BridgeMD
Extended Access of Momelotinib for Subjects with Myelofibrosis
EU CTIS ID: 2023-508018-41-00
What this study is testing
"To provide extended access to momelotinib and assess long-term safety in 4 cohorts of subjects who are currently receiving treatment with MMB and have not experienced progression of disease: - Cohort 1: Study GS-US-352-0101, subjects with PMF or post-PV/ET MF - Cohort 2: Study GS-US-352-1214, subjects with PMF or post-PV/ET MF - Cohort 3: Study GS-US-352-1154, subjects with PMF or post-PV/ET MF - Cohort 4: Study SRA-MMB-301, subjects with PMF or post PV/ET MF"
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- For subjects continuing MMB treatment: - Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
- For subjects continuing MMB treatment: - Able to comprehend and willing to sign the informed consent form
You likely can't join if
- Known hypersensitivity to MMB, its metabolites, or formulation excipient
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- Taiwan
- Canada
- Australia
- United States
- Singapore
- Korea, Republic of
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; Taiwan; Canada; Australia; United States; Singapore and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.